var bibbase_data = {"data":"\"Loading..\"\n\n
\n\n \n\n \n\n \n \n\n \n\n \n \n\n \n\n \n
\n generated by\n \n \"bibbase.org\"\n\n \n
\n \n\n
\n\n \n\n\n
\n\n Excellent! Next you can\n create a new website with this list, or\n embed it in an existing web page by copying & pasting\n any of the following snippets.\n\n
\n JavaScript\n (easiest)\n
\n \n <script src=\"https://bibbase.org/show?bib=http%3A%2F%2Fwww.bme.stonybrook.edu%2Flabs%2Fdbluestein%2FPublications-database.bib&jsonp=1&theme=side&css=www.bme.stonybrook.edu%2Flabs%2Fdbluestein%2Fcss%2Fbibbase.css&authorFirst=1&group0=type&filter=project:lvad&jsonp=1\"></script>\n \n
\n\n PHP\n
\n \n <?php\n $contents = file_get_contents(\"https://bibbase.org/show?bib=http%3A%2F%2Fwww.bme.stonybrook.edu%2Flabs%2Fdbluestein%2FPublications-database.bib&jsonp=1&theme=side&css=www.bme.stonybrook.edu%2Flabs%2Fdbluestein%2Fcss%2Fbibbase.css&authorFirst=1&group0=type&filter=project:lvad\");\n print_r($contents);\n ?>\n \n
\n\n iFrame\n (not recommended)\n
\n \n <iframe src=\"https://bibbase.org/show?bib=http%3A%2F%2Fwww.bme.stonybrook.edu%2Flabs%2Fdbluestein%2FPublications-database.bib&jsonp=1&theme=side&css=www.bme.stonybrook.edu%2Flabs%2Fdbluestein%2Fcss%2Fbibbase.css&authorFirst=1&group0=type&filter=project:lvad\"></iframe>\n \n
\n\n

\n For more details see the documention.\n

\n
\n
\n\n
\n\n This is a preview! To use this list on your own web site\n or create a new web site from it,\n create a free account. The file will be added\n and you will be able to edit it in the File Manager.\n We will show you instructions once you've created your account.\n
\n\n
\n\n

To the site owner:

\n\n

Action required! Mendeley is changing its\n API. In order to keep using Mendeley with BibBase past April\n 14th, you need to:\n

    \n
  1. renew the authorization for BibBase on Mendeley, and
    2. \n
  2. update the BibBase URL\n in your page the same way you did when you initially set up\n this page.\n
    3. \n
\n

\n\n

\n \n \n Fix it now\n

\n
\n\n
\n\n\n
\n \n \n
\n
\n  \n 1. Peer-Reviewed Journal Papers\n \n \n (12)\n \n \n
\n
\n \n \n
\n \n\n \n \n Li, M.; Walk, R.; Roka-Moiia, Y.; Sheriff, J.; Bluestein, D.; Barth, E.; and Slepian, M.\n\n\n \n \n \n \n \n Circulatory Loop Design and Components Introduce Artifacts Impacting In-Vitro Evaluation of Ventricular Assist Device Thrombogenicity: A Call for Caution.\n \n \n \n \n\n\n \n\n\n\n Artif Organs, 44: E226-E237. 2019.\n \n\n\n\n
\n\n\n\n \n \n \"Circulatory link\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 7 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{a109,\r\n author = {Li, M. and Walk, R. and Roka-Moiia, Y. and Sheriff, J. and Bluestein, D. and Barth, E.J. and Slepian, M.J.},\r\n year = {2019},\r\n title = {Circulatory Loop Design and Components Introduce Artifacts Impacting In-Vitro Evaluation of Ventricular Assist Device Thrombogenicity: A Call for Caution},\r\n journal = {Artif Organs},\r\n volume = {44},\r\n issue = {6},\r\n pages = {E226-E237},\r\n url_Link ={https://doi.org/10.1111/aor.13626},\r\n project = {activation; lvad},\r\n type    = {1. Peer-Reviewed Journal Papers},\r\n}\r\n\r\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n Apostoli, A.; Bianchi, V.; Bono, N.; Dimasi, A.; Ammann, K.; Roka-Moiia, Y.; Montisci, A.; Sheriff, J.; Bluestein, D.; Fiore, G.; Pappalardo, F.; Candiani, G.; Redaelli, A.; Slepian, M.; and Consolo, F.\n\n\n \n \n \n \n \n Prothrombotic Activity of Cytokine-Activated Endothelial Cells and Shear-Activated Platelets in the Setting of Ventricular Assist Device Support.\n \n \n \n \n\n\n \n\n\n\n J Heart Lung Transplant., 38: 658-667. 2019.\n \n\n\n\n
\n\n\n\n \n \n \"Prothrombotic link\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{a78,\r\n author = {Apostoli, A. and Bianchi, V. and Bono, N. and Dimasi, A. and Ammann, K.R. and Roka-Moiia, Y. and Montisci, A. and Sheriff, J. and Bluestein, D. and Fiore, G.B. and Pappalardo, F. and Candiani, G. and Redaelli, A. and Slepian, M.J. and Consolo, F.},\r\n year = {2019},\r\n title = {Prothrombotic Activity of Cytokine-Activated Endothelial Cells and Shear-Activated Platelets in the Setting of Ventricular Assist Device Support},\r\n journal = {J Heart Lung Transplant.},\r\n volume = {38},\r\n pages = {658-667},\r\n url_Link ={https://doi.org/10.1007/s11517-019-02012-y},\r\n project = {activation; lvad},\r\n type    = {1. Peer-Reviewed Journal Papers},\r\n}\r\n\r\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n Chiu, W.; Tran, P.; Khalpey, Z.; Lee, E.; Woo, Y.; Slepian, M.; and Bluestein, D.\n\n\n \n \n \n \n \n Device Thrombogenicity Emulation: An In Silico Predictor of In Vitro and In Vivo Ventricular Assist Device.\n \n \n \n \n\n\n \n\n\n\n Scientific Reports, 9: 2946. 2019.\n \n\n\n\n
\n\n\n\n \n \n \"Device link\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 3 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{a73,\r\n author = {Chiu, W-C and Tran, P.L. and Khalpey, Z. and Lee, E. and Woo, Y-R and Slepian, M.J. and Bluestein, D.},\r\n year = {2019},\r\n title = {Device Thrombogenicity Emulation: An In Silico Predictor of In Vitro and In Vivo Ventricular Assist Device},\r\n journal = {Scientific Reports},\r\n volume = {9: 2946},\r\n url_Link ={https://www.nature.com/articles/s41598-019-39897-6},\r\n project = {lvad},\r\n type    = {1. Peer-Reviewed Journal Papers},\r\n}\r\n\r\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n Selmi, M.; Chiu, W.; Keshav, V.; Melisurgo, G. B.; Mahr, C.; Aliseda, A.; Votta, E.; Redaelli, A.; Slepian, M.; Bluestein, D.; Pappalardo, F.; and Consolo, F.\n\n\n \n \n \n \n \n Blood damage in Left Ventricular Assist Devices: Pump thrombosis or system thrombosis?.\n \n \n \n \n\n\n \n\n\n\n The International Journal of Artificial Organs, 42: 113-124. 2018.\n \n\n\n\n
\n\n\n\n \n \n \"Blood link\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{a54,\r\n author = {Selmi, M. and Chiu, W.C. and Keshav, V. and Melisurgo, G. Beckman, J.A. and Mahr, C. and Aliseda, A. and Votta, E. and Redaelli, A. and Slepian, M.J. and Bluestein, D. and Pappalardo, F. and Consolo, F.},\r\n year = {2018},\r\n title = {Blood damage in Left Ventricular Assist Devices: Pump thrombosis or system thrombosis?},\r\n journal = {The International Journal of Artificial Organs},\r\n volume = {42},\r\n pages = {113-124},\r\n url_Link ={https://journals.sagepub.com/doi/abs/10.1177/0391398818806162?journalCode=jaoa},\r\n project = {lvad},\r\n type    = {1. Peer-Reviewed Journal Papers},\r\n}\r\n\r\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n Valerio, L.; Sheriff, J.; Tran, P. L.; Brengle, W.; Redaelli, A.; Fiore, G. B.; Pappalardo, F.; Bluestein, D.; and Slepian, M. J.\n\n\n \n \n \n \n \n Routine clinical anti-platelets have limited efficacy in modulating hypershear-mediated platelet activation associated with mechanical circulatory support.\n \n \n \n \n\n\n \n\n\n\n Thromb. Res., 163: 162-171. 2017.\n \n\n\n\n
\n\n\n\n \n \n \"Routine link\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{a40,\r\n author = {Valerio, L. and Sheriff, J. and Tran, P. L. and Brengle, W. and Redaelli, A. and Fiore, G. B. and Pappalardo, F. and Bluestein, D. and Slepian, M. J.},\r\n year = {2017},\r\n title = {Routine clinical anti-platelets have limited efficacy in modulating hypershear-mediated platelet activation associated with mechanical circulatory support},\r\n journal = {Thromb. Res.},\r\n volume = {163},\r\n pages = {162-171},\r\n abstract = {Introduction: Continuous flow ventricular assist devices (cfVADs) continue to be limited by thrombotic complications associated with disruptive flow patterns and supraphysiologic shear stresses. Patients are prescribed complex antiplatelet therapies, which do not fully prevent recurrent thromboembolic events. This is partially due to limited data on antiplatelet efficacy under cfVAD-associated shear conditions.\r\nMaterials and Methods: We investigated the efficacy of antiplatelet drugs directly acting on three pathways: (1) cyclooxygenase (aspirin), (2) phosphodiesterase (dipyridamole, pentoxifylline, cilostazol), and (3) glycoprotein IIb-IIIa (eptifibatide). Gel-filtered platelets treated with these drugs were exposed for 10 min to either constant shear stresses (30 dyne/cm2 and 70 dyne/cm2) or dynamic shear stress profiles extracted from simulated platelet trajectories through a cfVAD (Micromed DeBakey). Platelet activation state (PAS) was measured using a modified prothrombinase-based assay, with drug efficacy quantified based on PAS reduction compared to untreated controls.\r\nResults and Conclusions: Significant PAS reduction was observed for all drugs after exposure to 30 dyne/cm2 constant shear stress, and all drugs but dipyridamole after exposure to the 30th percentile shear stress waveform of the cfVAD. However, only cilostazol was significantly effective after 70 dyne/cm2 constant shear stress exposure, though no significant reduction was observed upon exposure to median shear stress conditions in the cfVAD. These results, coupled with the persistence of reported clinical thrombotic complication, suggest the need for the development of new classes of drugs that are especially designed to mitigate thrombosis in cfVAD patients, while reducing or eliminating the risk of bleeding.\r\n},\r\n url_Link ={https://dx.doi.org/10.1016/j.thromres.2017.12.001},\r\n project = {lvad},\r\n type    = {1. Peer-Reviewed Journal Papers},\r\n}\r\n\r\n
\n
\n\n\n
\n Introduction: Continuous flow ventricular assist devices (cfVADs) continue to be limited by thrombotic complications associated with disruptive flow patterns and supraphysiologic shear stresses. Patients are prescribed complex antiplatelet therapies, which do not fully prevent recurrent thromboembolic events. This is partially due to limited data on antiplatelet efficacy under cfVAD-associated shear conditions. Materials and Methods: We investigated the efficacy of antiplatelet drugs directly acting on three pathways: (1) cyclooxygenase (aspirin), (2) phosphodiesterase (dipyridamole, pentoxifylline, cilostazol), and (3) glycoprotein IIb-IIIa (eptifibatide). Gel-filtered platelets treated with these drugs were exposed for 10 min to either constant shear stresses (30 dyne/cm2 and 70 dyne/cm2) or dynamic shear stress profiles extracted from simulated platelet trajectories through a cfVAD (Micromed DeBakey). Platelet activation state (PAS) was measured using a modified prothrombinase-based assay, with drug efficacy quantified based on PAS reduction compared to untreated controls. Results and Conclusions: Significant PAS reduction was observed for all drugs after exposure to 30 dyne/cm2 constant shear stress, and all drugs but dipyridamole after exposure to the 30th percentile shear stress waveform of the cfVAD. However, only cilostazol was significantly effective after 70 dyne/cm2 constant shear stress exposure, though no significant reduction was observed upon exposure to median shear stress conditions in the cfVAD. These results, coupled with the persistence of reported clinical thrombotic complication, suggest the need for the development of new classes of drugs that are especially designed to mitigate thrombosis in cfVAD patients, while reducing or eliminating the risk of bleeding. \n
\n\n\n
\n\n\n
\n \n\n \n \n Dimasi, A.; Rasponi, M.; Consolo, F.; Fiore, G. B.; Bluestein, D.; Slepian, M. J.; and Redaelli, A.\n\n\n \n \n \n \n \n Microfludic platforms for the evaluation of anti-platelet agent efficacy under hyper-shear conditions associated with ventricular assist devices.\n \n \n \n \n\n\n \n\n\n\n Med. Eng. Phys., 48: 31-38. 2017.\n \n\n\n\n
\n\n\n\n \n \n \"Microfludic link\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{a27,\r\n author = {Dimasi, A. and Rasponi, M. and Consolo, F. and Fiore, G. B. and Bluestein, D. and Slepian, M. J. and Redaelli, A.},\r\n year = {2017},\r\n title = {Microfludic platforms for the evaluation of anti-platelet agent efficacy under hyper-shear conditions associated with ventricular assist devices},\r\n journal = {Med. Eng. Phys.},\r\n volume = {48},\r\n pages = {31-38},\r\n abstract = {Thrombus formation is a major adverse event affecting patients implanted with ventricular assist devices (VADs). Despite anti-thrombotic drug administration, thrombotic events remain frequent within the first year post-implantation. Platelet activation (PA) is an essential process underling thrombotic adverse events in VAD systems. Indeed, abnormal shear forces, correlating with specific flow trajectories of VADs, are strong agonists mediating PA. To date, the ability to determine efficacy of anti-platelet (AP) agents under shear stress conditions is limited. Here, we present a novel microfluidic platform designed to replicate shear stress patterns of a clinical VAD, and use it to compare the efficacy of two AP agents in vitro. Gel-filtered platelets were incubated with i) acetylsalicylic acid (ASA) and ii) ticagrelor, at two different concentrations (ASA: 125 and 250 µM; ticagrelor: 250 and 500 nM) and were circulated in the VAD-emulating microfluidic platform using a peristaltic pump. GFP was collected after 4 and 52 repetitions of exposure to the VAD shear pattern and tested for shear-mediated PA. ASA significantly inhibited PA only at 2-fold higher concentration (250 µM) than therapeutic dose (125 µM). The effect of ticagrelor was not dependent on drug concentration, and did not show significant inhibition with respect to untreated control. This study demonstrates the potential use of microfluidic platforms as means of testing platelet responsiveness and AP drug efficacy under complex and realistic VAD-like shear stress conditions.},\r\n url_Link ={https://doi.org/10.1016/j.medengphy.2017.08.005},\r\n project = {lvad},\r\n type    = {1. Peer-Reviewed Journal Papers},\r\n}\r\n\r\n
\n
\n\n\n
\n Thrombus formation is a major adverse event affecting patients implanted with ventricular assist devices (VADs). Despite anti-thrombotic drug administration, thrombotic events remain frequent within the first year post-implantation. Platelet activation (PA) is an essential process underling thrombotic adverse events in VAD systems. Indeed, abnormal shear forces, correlating with specific flow trajectories of VADs, are strong agonists mediating PA. To date, the ability to determine efficacy of anti-platelet (AP) agents under shear stress conditions is limited. Here, we present a novel microfluidic platform designed to replicate shear stress patterns of a clinical VAD, and use it to compare the efficacy of two AP agents in vitro. Gel-filtered platelets were incubated with i) acetylsalicylic acid (ASA) and ii) ticagrelor, at two different concentrations (ASA: 125 and 250 µM; ticagrelor: 250 and 500 nM) and were circulated in the VAD-emulating microfluidic platform using a peristaltic pump. GFP was collected after 4 and 52 repetitions of exposure to the VAD shear pattern and tested for shear-mediated PA. ASA significantly inhibited PA only at 2-fold higher concentration (250 µM) than therapeutic dose (125 µM). The effect of ticagrelor was not dependent on drug concentration, and did not show significant inhibition with respect to untreated control. This study demonstrates the potential use of microfluidic platforms as means of testing platelet responsiveness and AP drug efficacy under complex and realistic VAD-like shear stress conditions.\n
\n\n\n
\n\n\n
\n \n\n \n \n Chiu, W. C.; Alemu, Y.; McLarty, A.; Einav, S.; Slepian, M. J.; and Bluestein, D.\n\n\n \n \n \n \n \n Ventricular Assist Device Implantation Configurations Impact Overall Mechanical Circulatory Support System Thrombogenic Potential.\n \n \n \n \n\n\n \n\n\n\n ASAIO J., 63: 285-292. 2017.\n \n\n\n\n
\n\n\n\n \n \n \"Ventricular link\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@Article{a13,\r\n  author  = {Chiu, W-. C. and Alemu, Y. and McLarty, A. and Einav, S. and Slepian, M. J. and Bluestein, D.},\r\n  title   = {Ventricular Assist Device Implantation Configurations Impact Overall Mechanical Circulatory Support System Thrombogenic Potential},\r\n  journal = {ASAIO J.},\r\n  year    = {2017},\r\n  volume  = {63},\r\n  pages = {285-292},\r\n  abstract = {Ventricular assist devices (VADs) became in recent years the standard of care therapy for advanced heart failure with hemodynamic compromise. With the steadily growing population of device recipients, various postimplant complications have been reported, mostly associated with the hypershear generated by VADs that enhance their thrombogenicity by activating platelets. Although VAD design optimization can significantly improve its thromboresistance, the implanted VAD need to be evaluated as part of a system. Several clinical studies indicated that variability in implantation configurations may contribute to the overall system thrombogenicity. Numerical simulations were conducted in the HeartAssist 5 (HA5) and HeartMate II (HMII) VADs in the following implantation configurations: 1) inflow cannula angles: 115° and 140° (HA5); 2) three VAD circumferential orientations: 0°, 30°, and 60° (HA5 and HMII); and 3) 60° and 90° outflow graft anastomotic angles with respect to the ascending aorta (HA5). The stress accumulation of the platelets was calculated along flow trajectories and collapsed into a probability density function, representing the “thrombogenic footprint” of each configuration—a proxy to its thrombogenic potential (TP). The 140° HA5 cannula generated lower TP independent of the circumferential orientation of the VAD. Sixty-degree orientation generated the lowest TP for the HA5 versus 0° for the HMII. An anastomotic angle of 60° resulted in lower TP for HA5. These results demonstrate that optimizing the implantation configuration reduces the overall system TP. Thromboresistance can be enhanced by combining VAD design optimization with the surgical implantation configurations for achieving better clinical outcomes of implanted VADs.},\r\n  url_Link = {https://dx.doi.org/10.1097/MAT.0000000000000488},\r\n  project = {lvad},\r\n  type    = {1. Peer-Reviewed Journal Papers},\r\n}\r\n\r\n
\n
\n\n\n
\n Ventricular assist devices (VADs) became in recent years the standard of care therapy for advanced heart failure with hemodynamic compromise. With the steadily growing population of device recipients, various postimplant complications have been reported, mostly associated with the hypershear generated by VADs that enhance their thrombogenicity by activating platelets. Although VAD design optimization can significantly improve its thromboresistance, the implanted VAD need to be evaluated as part of a system. Several clinical studies indicated that variability in implantation configurations may contribute to the overall system thrombogenicity. Numerical simulations were conducted in the HeartAssist 5 (HA5) and HeartMate II (HMII) VADs in the following implantation configurations: 1) inflow cannula angles: 115° and 140° (HA5); 2) three VAD circumferential orientations: 0°, 30°, and 60° (HA5 and HMII); and 3) 60° and 90° outflow graft anastomotic angles with respect to the ascending aorta (HA5). The stress accumulation of the platelets was calculated along flow trajectories and collapsed into a probability density function, representing the “thrombogenic footprint” of each configuration—a proxy to its thrombogenic potential (TP). The 140° HA5 cannula generated lower TP independent of the circumferential orientation of the VAD. Sixty-degree orientation generated the lowest TP for the HA5 versus 0° for the HMII. An anastomotic angle of 60° resulted in lower TP for HA5. These results demonstrate that optimizing the implantation configuration reduces the overall system TP. Thromboresistance can be enhanced by combining VAD design optimization with the surgical implantation configurations for achieving better clinical outcomes of implanted VADs.\n
\n\n\n
\n\n\n
\n \n\n \n \n Slepian, M. J.; Sheriff, J.; Hutchinson, M.; Tran, P.; Bajaj, N.; Garcia, J. G. N.; Saavedra, S. S.; and Bluestein, D.\n\n\n \n \n \n \n \n Shear-Mediated Platelet Activation in the Free Flow: Perspectives on the Emerging Spectrum of Cell Mechanobiological Mechanisms Mediating Cardiovascular Implant Thrombosis.\n \n \n \n \n\n\n \n\n\n\n J. Biomech, 50: 20–25. 2017.\n \n\n\n\n
\n\n\n\n \n \n \"Shear-Mediated link\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{a10,\r\n author = {Slepian, M. J. and Sheriff, J. and Hutchinson, M. and Tran, P. and Bajaj, N. and Garcia, J. G. N. and Saavedra, S. S. and Bluestein, D.},\r\n year = {2017},\r\n title = {Shear-Mediated Platelet Activation in the Free Flow:  Perspectives on the Emerging Spectrum of Cell Mechanobiological Mechanisms Mediating Cardiovascular Implant Thrombosis},\r\n journal = {J. Biomech},\r\n volume = {50},\r\n pages = {20–25},\r\n abstract = {Shear-mediated platelet activation (SMPA) is central in thrombosis of implantable cardiovascular therapeutic devices. Despite the morbidity and mortality associated with thrombosis of these devices, our understanding of mechanisms operative in SMPA, particularly in free flowing blood, remains limited. Herein we present and discuss a range of emerging mechanisms for consideration for “free flow” activation under supraphysiologic shear. Further definition and manipulation of these mechanisms will afford opportunities for novel pharmacologic and mechanical strategies to limit SMPA and enhance overall implant device safety.},\r\n project = {activation and lvad},\r\n url_Link = {https://dx.doi.org/10.1016/j.jbiomech.2016.11.016},\r\n type = {1. Peer-Reviewed Journal Papers}\r\n}\r\n\r\n
\n
\n\n\n
\n Shear-mediated platelet activation (SMPA) is central in thrombosis of implantable cardiovascular therapeutic devices. Despite the morbidity and mortality associated with thrombosis of these devices, our understanding of mechanisms operative in SMPA, particularly in free flowing blood, remains limited. Herein we present and discuss a range of emerging mechanisms for consideration for “free flow” activation under supraphysiologic shear. Further definition and manipulation of these mechanisms will afford opportunities for novel pharmacologic and mechanical strategies to limit SMPA and enhance overall implant device safety.\n
\n\n\n
\n\n\n
\n \n\n \n \n Chiu, W. C.; Slepian, M. J.; and Bluestein, D.\n\n\n \n \n \n \n \n Thrombus Formation Patterns in the HeartMate II VAD - Clinical Observations Can Be Predicted by Numerical Simulations.\n \n \n \n \n\n\n \n\n\n\n ASAIO J, 60: 237-40. 2014.\n \n\n\n\n
\n\n\n\n \n \n \"Thrombus link\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{z22,\r\n author = {Chiu, W-. C. and Slepian, M. J. and Bluestein, D.},\r\n year = {2014},\r\n title = {Thrombus Formation Patterns in the HeartMate II VAD - Clinical Observations Can Be Predicted by Numerical Simulations},\r\n journal = {ASAIO J},\r\n volume = {60},\r\n issue = {2},\r\n pages = {237-40},\r\n url_Link = {https://doi.org/10.1097/MAT.0000000000000034},\r\n abstract = {Postimplant device thrombosis remains a life-threatening complication and limitation of continuous-flow ventricular assist devices (VADs). Using advanced computational fluid dynamic (CFD) simulations, we successfully depicted various flow patterns, recirculation zones, and stagnant platelet trajectories which promote thrombus formation and observed that they matched actual thrombus formation patterns observed in Thoratec HeartMate II VADs explanted from patients with pump thrombosis. Previously, these small eddies could not be captured by either digital particle image velocimetry or CFD due to insufficient resolution. Our study successfully demonstrated the potential capability of advanced CFD to be adopted for device optimization, leading to enhanced safety and efficacy of VADs for long-term destination therapy.},\r\n project = {lvad},\r\n type = {1. Peer-Reviewed Journal Papers}\r\n}\r\n\r\n
\n
\n\n\n
\n Postimplant device thrombosis remains a life-threatening complication and limitation of continuous-flow ventricular assist devices (VADs). Using advanced computational fluid dynamic (CFD) simulations, we successfully depicted various flow patterns, recirculation zones, and stagnant platelet trajectories which promote thrombus formation and observed that they matched actual thrombus formation patterns observed in Thoratec HeartMate II VADs explanted from patients with pump thrombosis. Previously, these small eddies could not be captured by either digital particle image velocimetry or CFD due to insufficient resolution. Our study successfully demonstrated the potential capability of advanced CFD to be adopted for device optimization, leading to enhanced safety and efficacy of VADs for long-term destination therapy.\n
\n\n\n
\n\n\n
\n \n\n \n \n Chiu, W. C.; Girdhar, G.; Xenos, M.; Alemu, Y.; Soares, J. S.; Einav, S.; Slepian, M. J.; and Bluestein, D.\n\n\n \n \n \n \n \n Thromboresistance Comparison of the HeartMate II Ventricular Assist Device with Device Thrombogenicity Emulation - optimized HeartAssist 5 VAD.\n \n \n \n \n\n\n \n\n\n\n J. Biomech. Eng, 136: 021014. 2014.\n \n\n\n\n
\n\n\n\n \n \n \"Thromboresistance link\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{z23,\r\n author = {Chiu, W-. C. and Girdhar, G. and Xenos, M. and Alemu, Y. and Soares, J. S. and Einav, S. and Slepian, M. J. and Bluestein, D.},\r\n year = {2014},\r\n title = {Thromboresistance Comparison of the HeartMate II Ventricular Assist Device with Device Thrombogenicity Emulation - optimized HeartAssist 5 VAD},\r\n journal = {J. Biomech. Eng},\r\n volume = {136},\r\n issue = {2},\r\n pages = {021014},\r\n url_Link = {https://doi.org/10.1115/1.4026254},\r\n abstract = {Approximately 7.5 x 106 patients in the US currently suffer from end-stage heart failure. The FDA has recently approved the designations of the Thoratec HeartMate II ventricular assist device (VAD) for both bridge-to-transplant and destination therapy (DT) due to its mechanical durability and improved hemodynamics. However, incidence of pump thrombosis and thromboembolic events remains high, and the life-long complex pharmacological regimens are mandatory in its VAD recipients. We have previously successfully applied our device thrombogenicity emulation (DTE) methodology for optimizing device thromboresistance to the Micromed Debakey VAD, and demonstrated that optimizing device features implicated in exposing blood to elevated shear stresses and exposure times significantly reduces shear-induced platelet activation and significantly improves the device thromboresistance. In the present study, we compared the thrombogenicity of the FDA-approved HeartMate II VAD with the DTE-optimized Debakey VAD (now labeled HeartAssist 5). With quantitative probability density functions of the stress accumulation along large number of platelet trajectories within each device which were extracted from numerical flow simulations in each device, and through measurements of platelet activation rates in recirculation flow loops, we specifically show that: (a) Platelets flowing through the HeartAssist 5 are exposed to significantly lower stress accumulation that lead to platelet activation than the HeartMate II, especially at the impeller-shroud gap regions (b) Thrombus formation patterns observed in the HeartMate II are absent in the HeartAssist 5 (c) Platelet activation rates (PAR) measured in vitro with the VADs mounted in recirculation flow-loops show a 2.5-fold significantly higher PAR value for the HeartMate II. This head to head thrombogenic performance comparative study of the two VADs, one optimized with the DTE methodology and one FDA-approved, demonstrates the efficacy of the DTE methodology for drastically reducing the device thrombogenic potential, validating the need for a robust in silico/in vitro optimization methodology for improving cardiovascular devices thromboresistance.},\r\n project = {lvad},\r\n type = {1. Peer-Reviewed Journal Papers}\r\n}\r\n\r\n
\n
\n\n\n
\n Approximately 7.5 x 106 patients in the US currently suffer from end-stage heart failure. The FDA has recently approved the designations of the Thoratec HeartMate II ventricular assist device (VAD) for both bridge-to-transplant and destination therapy (DT) due to its mechanical durability and improved hemodynamics. However, incidence of pump thrombosis and thromboembolic events remains high, and the life-long complex pharmacological regimens are mandatory in its VAD recipients. We have previously successfully applied our device thrombogenicity emulation (DTE) methodology for optimizing device thromboresistance to the Micromed Debakey VAD, and demonstrated that optimizing device features implicated in exposing blood to elevated shear stresses and exposure times significantly reduces shear-induced platelet activation and significantly improves the device thromboresistance. In the present study, we compared the thrombogenicity of the FDA-approved HeartMate II VAD with the DTE-optimized Debakey VAD (now labeled HeartAssist 5). With quantitative probability density functions of the stress accumulation along large number of platelet trajectories within each device which were extracted from numerical flow simulations in each device, and through measurements of platelet activation rates in recirculation flow loops, we specifically show that: (a) Platelets flowing through the HeartAssist 5 are exposed to significantly lower stress accumulation that lead to platelet activation than the HeartMate II, especially at the impeller-shroud gap regions (b) Thrombus formation patterns observed in the HeartMate II are absent in the HeartAssist 5 (c) Platelet activation rates (PAR) measured in vitro with the VADs mounted in recirculation flow-loops show a 2.5-fold significantly higher PAR value for the HeartMate II. This head to head thrombogenic performance comparative study of the two VADs, one optimized with the DTE methodology and one FDA-approved, demonstrates the efficacy of the DTE methodology for drastically reducing the device thrombogenic potential, validating the need for a robust in silico/in vitro optimization methodology for improving cardiovascular devices thromboresistance.\n
\n\n\n
\n\n\n
\n \n\n \n \n Sheriff, J.; Girdhar, G.; Chiu, W. C.; Jesty, J.; Slepian, M. J.; and Bluestein, D.\n\n\n \n \n \n \n \n Comparative efficacy of in vitro and in vivo metabolized aspirin in the DeBakey ventricular assist device.\n \n \n \n \n\n\n \n\n\n\n J. Thromb. Thrombolysis, 37: 499-506. 2014.\n \n\n\n\n
\n\n\n\n \n \n \"Comparative paper\n  \n \n \n \"Comparative link\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{z25,\r\n author = {Sheriff, J. and Girdhar, G. and Chiu, W-. C. and Jesty, J. and Slepian, M. J. and Bluestein, D.},\r\n year = {2014},\r\n title = {Comparative efficacy of in vitro and in vivo metabolized aspirin in the DeBakey ventricular assist device},\r\n journal = {J. Thromb. Thrombolysis},\r\n volume = {37},\r\n issue = {4},\r\n pages = {499-506},\r\n url_Paper={/labs/dbluestein/PDF/Sheriff_2014_aspirin_debakey_VAD.pdf},\r\n url_Link = {https://doi.org/10.1007/s11239-013-0997-6},\r\n abstract = {Ventricular assist devices (VADs) are implanted in patients with end-stage heart failure to provide both short- and long-term hemodynamic support. Unfortunately, bleeding and thromboembolic complications due to the severely disturbed, dynamic flow conditions generated within these devices require complex, long-term antiplatelet and anticoagulant therapy. While several studies have examined the effectiveness of one such agent, aspirin, under flow conditions, data comparing the efficacy of in vitro and in vivo metabolized aspirin is lacking. Two sets of studies were conducted in vitro with purified human platelets circulating for 30 min in a flow loop containing the DeBakey VAD (MicroMed Cardiovascular, Houston, TX, USA): (a) 20 muM aspirin was added exogenously in vitro to platelets isolated from aspirin-free subjects, and (b) platelets were obtained from donors 2 h (n = 14) and 20 h (n = 13) after ingestion of 1,000 mg aspirin. Near real-time platelet activation state (PAS) was measured with a modified prothrombinase-based assay. Platelets exposed to aspirin in vitro and in vivo (metabolized) showed 28.2 and 25.3 % reduction in platelet activation rate, respectively, compared to untreated controls. Our results demonstrate that in vitro treatment with antiplatelet drugs such as aspirin is as effective as in vivo metabolized aspirin in testing the effect of reducing shear-induced platelet activation in the VAD. Using the PAS assay provides a practical in vitro alternative to in vivo testing of antiplatelet efficacy, as well as for testing the thrombogenic performance of devices during their research and development.},\r\n project = {lvad},\r\n type = {1. Peer-Reviewed Journal Papers}\r\n}\r\n\r\n
\n
\n\n\n
\n Ventricular assist devices (VADs) are implanted in patients with end-stage heart failure to provide both short- and long-term hemodynamic support. Unfortunately, bleeding and thromboembolic complications due to the severely disturbed, dynamic flow conditions generated within these devices require complex, long-term antiplatelet and anticoagulant therapy. While several studies have examined the effectiveness of one such agent, aspirin, under flow conditions, data comparing the efficacy of in vitro and in vivo metabolized aspirin is lacking. Two sets of studies were conducted in vitro with purified human platelets circulating for 30 min in a flow loop containing the DeBakey VAD (MicroMed Cardiovascular, Houston, TX, USA): (a) 20 muM aspirin was added exogenously in vitro to platelets isolated from aspirin-free subjects, and (b) platelets were obtained from donors 2 h (n = 14) and 20 h (n = 13) after ingestion of 1,000 mg aspirin. Near real-time platelet activation state (PAS) was measured with a modified prothrombinase-based assay. Platelets exposed to aspirin in vitro and in vivo (metabolized) showed 28.2 and 25.3 % reduction in platelet activation rate, respectively, compared to untreated controls. Our results demonstrate that in vitro treatment with antiplatelet drugs such as aspirin is as effective as in vivo metabolized aspirin in testing the effect of reducing shear-induced platelet activation in the VAD. Using the PAS assay provides a practical in vitro alternative to in vivo testing of antiplatelet efficacy, as well as for testing the thrombogenic performance of devices during their research and development.\n
\n\n\n
\n\n\n
\n \n\n \n \n Bluestein, D.; Girdhar, G.; Einav, S.; and Slepian, M. J.\n\n\n \n \n \n \n \n Device thrombogenicity emulation: A novel methodology for optimizing the thromboresistance of cardiovascular devices.\n \n \n \n \n\n\n \n\n\n\n J. Biomech, 46: 338-344. Erratum in: 46(7):1413. 2013.\n \n\n\n\n
\n\n\n\n \n \n \"Device paper\n  \n \n \n \"Device link\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{z34,\r\n author = {Bluestein, D. and Girdhar, G. and Einav, S. and Slepian, M. J.},\r\n year = {2013},\r\n title = {Device thrombogenicity emulation: A novel methodology for optimizing the thromboresistance of cardiovascular devices},\r\n journal = {J. Biomech},\r\n volume = {46},\r\n issue = {2},\r\n pages = {338-344. Erratum in: 46(7):1413},\r\n url_Paper={/labs/dbluestein/PDF/Bluestein_2013_DTE_thromboresistance.pdf},\r\n url_Link = {https://doi.org/10.1016/j.jbiomech.2012.11.033},\r\n abstract = {Thrombotic complications with mechanical circulatory support (MCS) devices remain a critical limitation to their long-term use. Device-induced shear forces may enhance the thrombotic potential of MCS devices through chronic activation of platelets, with a known dose-time response of the platelets to the accumulated stress experienced while flowing through the device-mandating complex, lifelong anticoagulation therapy. To enhance the thromboresistance of these devices for facilitating their long-term use, a universal predictive methodology entitled device thrombogenicity emulation (DTE) was developed. DTE is aimed at optimizing the thromboresistance of any MCS device. It is designed to test device-mediated thrombogenicity, coupled with virtual design modifications, in an iterative approach. This disruptive technology combines in silico numerical simulations with in vitro measurements, by correlating device hemodynamics with platelet activity coagulation markers-before and after iterative design modifications aimed at achieving optimized thrombogenic performance. The design changes are first tested in the numerical domain, and the resultant device conditions are then emulated in a hemodynamic shearing device (HSD) in which platelet activity is measured under device emulated conditions. As such, DTE can be easily incorporated during the device research and development phase-achieving minimization of the device thrombogenicity before prototypes are built and tested thereby reducing the ultimate cost of preclinical and clinical trials. The robust capability of this predictive technology is demonstrated here in various MCS devices. The presented examples indicate the potential of DTE for reducing device thrombogenicity to a level that may obviate or significantly reduce the extent of anticoagulation currently mandated for patients implanted with MCS devices for safe long-term clinical use.},\r\n project = {lvad},\r\n type = {1. Peer-Reviewed Journal Papers}\r\n}\r\n\r\n
\n
\n\n\n
\n Thrombotic complications with mechanical circulatory support (MCS) devices remain a critical limitation to their long-term use. Device-induced shear forces may enhance the thrombotic potential of MCS devices through chronic activation of platelets, with a known dose-time response of the platelets to the accumulated stress experienced while flowing through the device-mandating complex, lifelong anticoagulation therapy. To enhance the thromboresistance of these devices for facilitating their long-term use, a universal predictive methodology entitled device thrombogenicity emulation (DTE) was developed. DTE is aimed at optimizing the thromboresistance of any MCS device. It is designed to test device-mediated thrombogenicity, coupled with virtual design modifications, in an iterative approach. This disruptive technology combines in silico numerical simulations with in vitro measurements, by correlating device hemodynamics with platelet activity coagulation markers-before and after iterative design modifications aimed at achieving optimized thrombogenic performance. The design changes are first tested in the numerical domain, and the resultant device conditions are then emulated in a hemodynamic shearing device (HSD) in which platelet activity is measured under device emulated conditions. As such, DTE can be easily incorporated during the device research and development phase-achieving minimization of the device thrombogenicity before prototypes are built and tested thereby reducing the ultimate cost of preclinical and clinical trials. The robust capability of this predictive technology is demonstrated here in various MCS devices. The presented examples indicate the potential of DTE for reducing device thrombogenicity to a level that may obviate or significantly reduce the extent of anticoagulation currently mandated for patients implanted with MCS devices for safe long-term clinical use.\n
\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2. Invited Papers\n \n \n (2)\n \n \n
\n
\n \n \n
\n \n\n \n \n Bluestein, D.; Dewey Jr., C. F.; Elad, D.; Gharib, M.; Kamm, R. D.; Lieber, B. B.; Margulies, S. S.; Slepian, M. J.; Tarbell, J.; and Weinbaum, S.\n\n\n \n \n \n \n \n In Memoriam: Shmuel Einav, 1942–2022.\n \n \n \n \n\n\n \n\n\n\n J Biomech Eng, 144: 080101. 2022.\n \n\n\n\n
\n\n\n\n \n \n \"In link\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{a171,\r\n author = {Bluestein, D. and Dewey Jr., C. F. and Elad, D. and Gharib, M. and Kamm, R. D. and Lieber, B. B. and Margulies, S. S. and Slepian, M. J. and Tarbell, J. and Weinbaum, S.},\r\n year = {2022},\r\n title = {In Memoriam: Shmuel Einav, 1942–2022},\r\n journal = {J Biomech Eng},\r\n volume = {144},\r\n pages = {080101},\r\n url_Link ={https://doi.org/10.1115/1.4054797},\r\n project = {lvad},\r\n type    = {2. Invited Papers},\r\n }\r\n\r\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n Slepian, M. J.; Italiano, J.; Bluestein, D.; Sheriff, J.; and Roka-Moiia, Y.\n\n\n \n \n \n \n \n Evolving perspectives on mechanical circulatory support biocompatibility and interfaces.\n \n \n \n \n\n\n \n\n\n\n Ann Cardiothorac Surg, 10: 396-398. 2021.\n \n\n\n\n
\n\n\n\n \n \n \"Evolving link\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 3 downloads\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{a152,\r\n author = {Slepian, M. J. and Italiano, J. and Bluestein, D. and Sheriff, J. and Roka-Moiia, Y.},\r\n year = {2021},\r\n title = {Evolving perspectives on mechanical circulatory support biocompatibility and interfaces},\r\n journal = {Ann Cardiothorac Surg},\r\n volume = {10},\r\n issue = {3},\r\n pages = {396-398},\r\n url_Link ={https://doi.org/10.1007/s10439-021-02790-3},\r\n project = {lvad},\r\n type    = {2. Invited Papers},\r\n}\r\n\r\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 6. Abstracts\n \n \n (16)\n \n \n
\n
\n \n \n
\n \n\n \n \n Palomares, D. E.; Jason, L.; Tran, P. L.; Sheriff, J.; Bluestein, D.; and Slepian, M. J.\n\n\n \n \n \n \n VAD Derived Mechano-Acoustics Lead to Platelet Activation.\n \n \n \n\n\n \n\n\n\n In Virtual ASAIO Conference, Virtual, June 2020. \n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@inproceedings{a125,\r\n author = {Palomares, D. E. and Jason, L. and Tran, P. L. and Sheriff, J. and Bluestein, D. and Slepian, M. J.},\r\n year = {2020},\r\n title = {VAD Derived Mechano-Acoustics Lead to Platelet Activation},\r\n booktitle = {Virtual ASAIO Conference},\r\n address = {Virtual},\r\n month = {June},\r\n project = {activation; lvad},\r\n type = {6. Abstracts}\r\n}\r\n\r\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n Roka-Moiia, Y.; Lewis, S.; Sheriff, J.; Italiano, J. E.; Bluestein, D.; and Slepian, M. J.\n\n\n \n \n \n \n Membrane Scrambling Induced by MCS-Related Shear Stress is not Associated with Platelet Apoptosis.\n \n \n \n\n\n \n\n\n\n In Virtual ASAIO Conference, Virtual, June 2020. \n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@inproceedings{a123,\r\n author = {Roka-Moiia, Y. and Lewis, S. and Sheriff, J. and Italiano, J. E. and Bluestein, D. and Slepian, M. J.},\r\n year = {2020},\r\n title = {Membrane Scrambling Induced by MCS-Related Shear Stress is not Associated with Platelet Apoptosis},\r\n booktitle = {Virtual ASAIO Conference},\r\n address = {Virtual},\r\n month = {June},\r\n project = {activation; lvad},\r\n type = {6. Abstracts}\r\n}\r\n\r\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n Roka-Moiia, Y.; Lewis, S.; Sheriff, J.; Italiano, J. E.; Bluestein, D.; and Slepian, M. J.\n\n\n \n \n \n \n MCS Shear Stress Exposure Induces Platelet Mitochondrial Membrane Depolarization and Scrambling Without Inducing Apoptosis.\n \n \n \n\n\n \n\n\n\n In Virtual ASAIO Conference, Virtual, June 2020. \n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@inproceedings{a120,\r\n author = {Roka-Moiia, Y. and Lewis, S. and Sheriff, J. and Italiano, J. E. and Bluestein, D. and Slepian, M. J.},\r\n year = {2020},\r\n title = {MCS Shear Stress Exposure Induces Platelet Mitochondrial Membrane Depolarization and Scrambling Without Inducing Apoptosis},\r\n booktitle = {Virtual ASAIO Conference},\r\n address = {Virtual},\r\n month = {June},\r\n project = {activation; lvad},\r\n type = {6. Abstracts}\r\n}\r\n\r\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n Palomares, D. E.; Jensen, L.; Le, P.; Ammann, K.; Liu, Y.; Sheriff, J.; Bluestein, D.; and Slepian, M. J.\n\n\n \n \n \n \n Mechano-Acoustic Mediated Platelet Activation in Ventricular Assist Devices.\n \n \n \n\n\n \n\n\n\n In Virtual ASAIO Conference, Virtual, June 2020. \n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@inproceedings{a119,\r\n author = {Palomares, D. E. and Jensen, L. and Le, P. and Ammann, K. and Liu, Y. and Sheriff, J. and Bluestein, D. and Slepian, M. J.},\r\n year = {2020},\r\n title = {Mechano-Acoustic Mediated Platelet Activation in Ventricular Assist Devices},\r\n booktitle = {Virtual ASAIO Conference},\r\n address = {Virtual},\r\n month = {June},\r\n project = {activation; lvad},\r\n type = {6. Abstracts}\r\n}\r\n\r\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n Palomares, D. E.; Jensen, L.; Le, P.; Ammann, K.; Liu, Y.; Sheriff, J.; Bluestein, D.; and Slepian, M. J.\n\n\n \n \n \n \n Mechano-Acoustic Mediated Platelet Activation in Ventricular Assist Devices.\n \n \n \n\n\n \n\n\n\n In Virtual ASAIO Conference, Virtual, June 2020. \n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@inproceedings{a118,\r\n author = {Palomares, D. E. and Jensen, L. and Le, P. and Ammann, K. and Liu, Y. and Sheriff, J. and Bluestein, D. and Slepian, M. J.},\r\n year = {2020},\r\n title = {Mechano-Acoustic Mediated Platelet Activation in Ventricular Assist Devices},\r\n booktitle = {Virtual ASAIO Conference},\r\n address = {Virtual},\r\n month = {June},\r\n project = {activation; lvad},\r\n type = {6. Abstracts}\r\n}\r\n\r\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n Roka-Moiia, Y.; Italiano, J.; Sheriff, J.; Bluestein, D.; and Slepian, M.\n\n\n \n \n \n \n Yin and Yang of MCS-Related Coagulopathy: Shear Stress Promotes Platelet Prothrombosis and Microparticle Generation While Inducing Integrin Downregulation and Decreased Aggregability.\n \n \n \n\n\n \n\n\n\n In International Society for Heart and Lung Transplantation (ISHLT) 2020 Annual Meeting (Canceled), Montreal, Canada, April 22-25 2020. \n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@inproceedings{a112,\r\n author = {Roka-Moiia, Y. and Italiano, J. and Sheriff, J. and Bluestein, D. and Slepian, M.J.},\r\n year = {2020},\r\n title = {Yin and Yang of MCS-Related Coagulopathy: Shear Stress Promotes Platelet Prothrombosis and Microparticle Generation While Inducing Integrin Downregulation and Decreased Aggregability},\r\n booktitle = {International Society for Heart and Lung Transplantation (ISHLT) 2020 Annual Meeting (Canceled)},\r\n address = {Montreal, Canada},\r\n month = {April 22-25},\r\n project = {activation; lvad},\r\n type = {6. Abstracts}\r\n}\r\n\r\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n Sweedo, A.; Wise, L. M.; Sheriff, J.; Bluestein, D.; Purdy, J. G.; and Slepian, M. J.\n\n\n \n \n \n \n MCS Hypershear Modulates Platelet Membrane Fluidity, Lipid Species, and is Gender Specific.\n \n \n \n\n\n \n\n\n\n In International Society for Heart and Lung Transplantation (ISHLT) 2020 Annual Meeting (Canceled), Montreal, Canada, April 22-25 2020. \n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@inproceedings{a111,\r\n author = {Sweedo, A. and Wise, L. M. and Sheriff, J. and Bluestein, D. and Purdy, J. G. and Slepian, M. J.},\r\n year = {2020},\r\n title = {MCS Hypershear Modulates Platelet Membrane Fluidity, Lipid Species, and is Gender Specific},\r\n booktitle = {International Society for Heart and Lung Transplantation (ISHLT) 2020 Annual Meeting (Canceled)},\r\n address = {Montreal, Canada},\r\n month = {April 22-25},\r\n project = {activation; lvad},\r\n type = {6. Abstracts}\r\n}\r\n\r\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n Roka-Moiia, Y.; Palomares, D.; Italiano, J.; Sheriff, J.; Bluestein, D.; and Slepian, M.\n\n\n \n \n \n \n The “Thrombosis-Bleeding Paradox” of Mechanical Circulatory Support: Shear Stress Promotes Platelet Prothrombosis and Mcroparticle Generation While Inducing Integrin αIIbβ3 Shedding and Decreased Aggregability.\n \n \n \n\n\n \n\n\n\n In AHA Scientific Sessions 2019, Philadelphia, PA, November 16-19 2019. \n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@inproceedings{a105,\r\n author = {Roka-Moiia, Y. and Palomares, D.E. and Italiano, J.E. and Sheriff, J. and Bluestein, D. and Slepian, M.J.},\r\n year = {2019},\r\n title = {The “Thrombosis-Bleeding Paradox” of Mechanical Circulatory Support: Shear Stress Promotes Platelet Prothrombosis and Mcroparticle Generation While Inducing Integrin αIIbβ3 Shedding and Decreased Aggregability},\r\n booktitle = {AHA Scientific Sessions 2019},\r\n address = {Philadelphia, PA},\r\n month = {November 16-19},\r\n project = {lvad; activation},\r\n type = {6. Abstracts}\r\n}\r\n\r\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n Roka-Moiia, Y.; Harhash, A.; Muslmani, S.; Sheriff, J.; Bluestein, D.; Kern, K.; and Slepian, M.\n\n\n \n \n \n \n Shear-Mediated Activation Promotes Platelet Procoagulant Activity And Microparticle Generation In Pigs Following Short-Term ECMO Support.\n \n \n \n\n\n \n\n\n\n In 27th ISMCS Annual Meeting, Bologna, Italy, October 21-23 2019. \n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@inproceedings{a102,\r\n author = {Roka-Moiia, Y. and Harhash, A. and Muslmani, S. and Sheriff, J. and Bluestein, D. and Kern, K. and Slepian, M.J.},\r\n year = {2019},\r\n title = {Shear-Mediated Activation Promotes Platelet Procoagulant Activity And Microparticle Generation In Pigs Following Short-Term ECMO Support},\r\n booktitle = {27th ISMCS Annual Meeting},\r\n address = {Bologna, Italy},\r\n month = {October 21-23},\r\n project = {lvad; activation},\r\n type = {6. Abstracts}\r\n}\r\n\r\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n Roka-Moiia, Y.; Sheriff, J.; Bluestein, D.; and Slepian, M.\n\n\n \n \n \n \n P2Y12 Receptor Agonists: Do They Really Inhibit Shear-Mediated Platelet Activation within MCS?.\n \n \n \n\n\n \n\n\n\n In 39th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT), Orlando, FL, April 3-6 2019. \n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@inproceedings{a85,\r\n author = {Roka-Moiia, Y. and Sheriff, J. and Bluestein, D. and Slepian, M.J.},\r\n year = {2019},\r\n title = {P2Y12 Receptor Agonists: Do They Really Inhibit Shear-Mediated Platelet Activation within MCS?},\r\n booktitle = {39th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT)},\r\n address = {Orlando, FL},\r\n month = {April 3-6},\r\n project = {activation; lvad},\r\n type = {6. Abstracts}\r\n}\r\n\r\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n Sweedo, A.; Wise, L.; Roka-Moiia, Y.; Sheriff, J.; Bluestein, D.; Purdy, J.; and Slepian, M.\n\n\n \n \n \n \n Elevated Shear Associated with MCS Devices Yields Unique Platelet Membrane Lipid Species: Pro-Thrombotic Agonists?.\n \n \n \n\n\n \n\n\n\n In 39th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT), Orlando, FL, April 3-6 2019. \n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@inproceedings{a84,\r\n author = {Sweedo, A. and Wise, L.M. and Roka-Moiia, Y. and Sheriff, J. and Bluestein, D. and Purdy, J.G. and Slepian, M.J.},\r\n year = {2019},\r\n title = {Elevated Shear Associated with MCS Devices Yields Unique Platelet Membrane Lipid Species: Pro-Thrombotic Agonists?},\r\n booktitle = {39th Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (ISHLT)},\r\n address = {Orlando, FL},\r\n month = {April 3-6},\r\n project = {activation; lvad},\r\n type = {6. Abstracts}\r\n}\r\n\r\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n Chiu, W. C.; Tran, P. L.; Khalpey, Z.; Slepian, M. J.; and Bluestein, D.\n\n\n \n \n \n \n In vivo validation of the device thrombogenicity emulation methodology.\n \n \n \n\n\n \n\n\n\n In 25th Annual Scientific Congress of the International Society of Mechanical Circulatory Support (ISMCS), Tucson, AZ, October 15-18 2017. \n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@inproceedings{a37,\r\n author = {Chiu, W-. C. and Tran, P. L. and Khalpey, Z. and Slepian, M. J. and Bluestein, D.},\r\n year = {2017},\r\n title = {In vivo validation of the device thrombogenicity emulation methodology},\r\n booktitle = {25th Annual Scientific Congress of the International Society of Mechanical Circulatory Support (ISMCS)},\r\n address = {Tucson, AZ},\r\n month = {October 15-18},\r\n project = {lvad},\r\n type = {6. Abstracts}\r\n}\r\n\r\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n Tran, P. L.; Hutchinson, M.; Valerio, L.; Brengle, W.; Betterton, E.; Kazui, T.; Khalpey, Z. I.; Sheriff, J.; Bluestein, D.; and Slepian, M. J.\n\n\n \n \n \n \n Platelet activity state assay of a Heartmate II patient with multiple recurrent thrombosis.\n \n \n \n\n\n \n\n\n\n In 25th Annual Scientific Congress of the International Society of Mechanical Circulatory Support (ISMCS), Tucson, AZ, October 15-18 2017. \n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@inproceedings{a34,\r\n author = {Tran, P. L. and Hutchinson, M. and Valerio, L. and Brengle, W. and Betterton, E. and Kazui, T. and Khalpey, Z. I. and Sheriff, J. and Bluestein, D. and Slepian, M. J.},\r\n year = {2017},\r\n title = {Platelet activity state assay of a Heartmate II patient with multiple recurrent thrombosis},\r\n booktitle = {25th Annual Scientific Congress of the International Society of Mechanical Circulatory Support (ISMCS)},\r\n address = {Tucson, AZ},\r\n month = {October 15-18},\r\n project = {activation, lvad},\r\n type = {6. Abstracts}\r\n}\r\n\r\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n Walk, R.; Palomares, D.; Roka-Moiia, Y.; Bluestein, D.; and Slepian, M. J.\n\n\n \n \n \n \n The importance of angle: effect of aorta-VAD outflow graft anastomosis angle on platelet activation.\n \n \n \n\n\n \n\n\n\n In 25th Annual Scientific Congress of the International Society of Mechanical Circulatory Support (ISMCS), Tucson, AZ, October 15-18 2017. \n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@inproceedings{a32,\r\n author = {Walk, R. and Palomares, D. and Roka-Moiia, Y. and Bluestein, D. and Slepian, M. J.},\r\n year = {2017},\r\n title = {The importance of angle: effect of aorta-VAD outflow graft anastomosis angle on platelet activation},\r\n booktitle = {25th Annual Scientific Congress of the International Society of Mechanical Circulatory Support (ISMCS)},\r\n address = {Tucson, AZ},\r\n month = {October 15-18},\r\n project = {lvad},\r\n type = {6. Abstracts}\r\n}\r\n\r\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n Sheriff, J.; Tran, P. L.; Valerio, L.; Hutchinson, M.; Brengle, W.; Slepian, M. J.; and Bluestein, D.\n\n\n \n \n \n \n Efficacy of antiplatelet drugs on shear-mediated platelet activation in ventricular assist devices.\n \n \n \n\n\n \n\n\n\n In BMES Annual Fall Meeting 2016, Minneapolis, MN, October 5-8 2016. \n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@inproceedings{a8,\r\n author = {Sheriff, J. and Tran, P. L. and Valerio, L. and Hutchinson, M. and Brengle, W. and Slepian, M. J. and Bluestein, D.},\r\n year = {2016},\r\n title = {Efficacy of antiplatelet drugs on shear-mediated platelet activation in ventricular assist devices},\r\n booktitle = {BMES Annual Fall Meeting 2016},\r\n address = {Minneapolis, MN},\r\n month = {October 5-8},\r\n project = {activation and lvad},\r\n type = {6. Abstracts}\r\n}\r\n\r\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n Dimasi, A.; Consolo, F.; Rasponi, M.; Fiore, G. B.; Valerio, L.; Pappalardo, F.; Bluestein, D.; Slepian, M. J.; and Redaelli, A.\n\n\n \n \n \n \n Lab-on-a-Chip microfluidic platforms to monitor the shear-induced thrombotic risk in blood contacting devices.\n \n \n \n\n\n \n\n\n\n In 5th Micro and Nano Flows Conference, Milan, Italy, September 11-14 2016. \n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@inproceedings{a1022,\r\n author = {Dimasi, A. and Consolo, F. and Rasponi, M. and Fiore, G. B. and Valerio, L. and Pappalardo, F. and Bluestein, D. and Slepian, M. J. and Redaelli, A.},\r\n year = {2016},\r\n title = {Lab-on-a-Chip microfluidic platforms to monitor the shear-induced thrombotic risk in blood contacting devices},\r\n booktitle = {5th Micro and Nano Flows Conference},\r\n address = {Milan, Italy},\r\n month = {September 11-14},\r\n project = {lvad},\r\n type = {6. Abstracts}\r\n}\r\n\r\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n\n\n\n
\n\n\n \n\n \n \n \n \n\n
\n"}; document.write(bibbase_data.data);